Business Wire

Mavenir Introduces Converged Packet Core Solution for Hybrid and Multi-Cloud Deployment with Red Hat

Share

Mavenir, the Network Software Provider building the future of networks with cloud-native solutions that run on any cloud, today announced that it has launched its Converged Packet Core solution running on Red Hat OpenShift, delivering a fully containerized and automated solution built on a services-based open architecture for public, private, hybrid, edge and on-premises cloud deployment. It runs on general-purpose, commercial-off-the-shelf (COTS) hardware available from market-leading server vendors and can be deployed and operated without any dependencies on the underlying infrastructure, making the network flexible, agile, and programmable.

The integrated solution is being deployed by six tier-1 and tier-2 service providers in global markets including Europe, North America and Asia.

The integrated solution delivers a comprehensive, carrier-grade end-to-end stack, from the operating system to the cloud-native network functions (CNFs), designed for the telecommunication industry. It comes pre-configured with features such as automated 5G core deployment, centralized monitoring framework, and tools for the management of the packet core and cloud infrastructure, including planning, deployment and support. This integrated solution lowers the barrier to entry for CSPs and enterprises deploying 4G and 5G public and private networks with real-time use cases that require on-premises equipment. The entire end-to-end telco stack is validated by Mavenir and addresses multiple customer requirements discovered through Mavenir’s and Red Hat’s extensive experience with planning and deployment of cloud-based services for CSPs.

Mavenir’s Converged Packet Core runs on Red Hat OpenShift and can be deployed in any combination of network models such as 2G/3G, 4G, 5G SA (standalone), and 5G NSA (non-standalone) delivering the following benefits for service providers:

> Accelerated deployment — as a pre-integrated, pre-engineered solution that is ready to deploy with minimal planning

> Cost efficiencies — by reducing on-premises cloud infrastructure overhead and leveraging general-purpose COTS hardware

> Lower hardware footprint than other competing on-premises cloud solutions

> Continuous Innovation — with DevOps-based CI/CD software release and upgrade cycles that reduce time to market of new capabilities

> Security features, development speed, and flexibility with the addition of Red Hat OpenShift

“Some operators are unfamiliar with containers and cloud so a solution from a single, reliable vendor that can offer an integrated end-to-end, turnkey solution is essential for their success,” said Ashok Khuntia, President, Core Networks, Mavenir. “By collaborating with Red Hat, Mavenir extends the reach of its Converged Packet Core support public, private, hybrid and on-premises deployments, with built-in automation, better cost efficiencies and less complexity.”

“Architectures and operating models of networks are undergoing a fundamental shift by moving to the cloud. Red Hat is excited to work with our ecosystem partners to deliver innovative open hybrid cloud technologies to help service providers modernize and make 5G a reality.” said Honoré LaBourdette, Vice President, Telco, Media, Entertainment & Edge Ecosystem, Red Hat. “With Red Hat OpenShift, the Mavenir Converged Packet Core solution will help service providers become better equipped to meet unique network requirements on a trusted, agile open source platform.”

Mavenir’s Converged Packet Core runs on a scalable platform that allows communications service providers (CSPs) to deploy the same core for multiple use cases, such as Enhanced Mobile Broadband (eMBB), Fixed Wireless Access (FWA), Internet of Things (IoT) offerings, and private and edge networks for different industry verticals.

Red Hat OpenShift provides organizations with the ability to deploy on any hybrid or multi-cloud cloud environment with a fast, flexible and easy-to-manage platform that speeds up application development and extends control over distributed resources.

To know more about this collaboration, visit Mavenir (hall 2 stand 2H60) or Red Hat (hall 2 stand 2F30) at MWC 2023.

Red Hat and OpenShift are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries.

About Mavenir:

Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mavenir PR Contacts:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye